Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
84.34
+0.10 (0.12%)
Apr 2, 2026, 4:00 PM EDT - Market closed
Apogee Therapeutics Employees
Apogee Therapeutics had 261 employees as of December 31, 2025. The number of employees increased by 65 or 33.16% compared to the previous year.
Employees
261
Change (1Y)
65
Growth (1Y)
33.16%
Revenue / Employee
n/a
Profits / Employee
-$980,241
Market Cap
6.23B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 261 | 65 | 33.16% |
| Dec 31, 2024 | 196 | 105 | 115.38% |
| Dec 31, 2023 | 91 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Rhythm Pharmaceuticals | 414 |
| Mirum Pharmaceuticals | 372 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| Arcellx | 209 |
| CG Oncology | 142 |
| Protagonist Therapeutics | 132 |
APGE News
- 9 days ago - Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million - GlobeNewsWire
- 11 days ago - Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering - GlobeNewsWire
- 12 days ago - Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone - Seeking Alpha
- 12 days ago - Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript - Seeking Alpha
- 12 days ago - Apogee Therapeutics: Two Shots A Year, One Shot At Disruption - Seeking Alpha
- 12 days ago - Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering - GlobeNewsWire
- 13 days ago - Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout - Benzinga
- 13 days ago - Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis - GlobeNewsWire